Novartis meningitis vaccine used at 2nd US campus

(AP)—Swiss drug maker Novartis says a second U.S. university is using its new vaccine against meningitis B.

Novartis said Monday that the , Bexsero, is being used at the University of California Santa Barbara until March 7 to help protect 20,000 students and staff after an .

The vaccine shot for the B strain of the meningitis bacteria is approved for use in Europe, Australia and Canada, but not yet for general use in the United States.

But the U.S. Food and Drug Administration has now approved the use of Bexsero twice in response to outbreaks at U.S. college campuses. It is the first vaccine against the B strain of meningitis.

Princeton University says almost 5,300 people got the vaccine last year in an effort to halt an outbreak there.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Princeton vaccine reaches 90 percent of eligible

Dec 13, 2013

Princeton University officials say more than 90 percent of the eligible students and staff received a meningitis vaccine this week as part of the university's effort to halt an outbreak.

Recommended for you

Added benefit of vedolizumab is not proven

5 hours ago

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments